Abstract：
There are few reported cases of ALK gene rearranged (ALK+) non-small cell lung cancer (NSCLC) during pregnancy. There is a lack of information on the safety of ALK inhibitors in pregnant patients. We present a 25-year-old African American woman who was diagnosed with metastatic ALK+ lung adenocarcinoma at 15 weeks of gestation. Treatment with alectinib was initiated at 18 weeks\' gestation with resultant radiological treatment response. The patient did not experience any adverse effects from alectinib during her pregnancy. An elective induction of labor at 39 weeks resulted in an uncomplicated vaginal delivery. This case adds to available data and provides insight on the safety of using alectinib in a pregnant, ALK+ NSCLC patient, allowing the patient to continue her pregnancy to term while treating advanced lung adenocarcinoma.
摘要：
妊娠期ALK基因重排(ALK+)非小细胞肺癌(NSCLC)的报道较少。缺乏有关ALK抑制剂在妊娠患者中安全性的信息。我们介绍了一名25岁的非洲裔美国妇女，她在妊娠15周时被诊断为转移性ALK肺腺癌。在妊娠18周时开始使用alectinib治疗，并产生放射学治疗反应。患者在怀孕期间没有经历阿来替尼的任何不良反应。在第39周时进行选择性引产导致了简单的阴道分娩。此病例增加了现有数据，并提供了有关在孕妇中使用阿来替尼的安全性的见解。ALK+NSCLC患者，允许患者在治疗晚期肺腺癌的同时继续怀孕至足月。
